- Home
- RCUS vs NAVN Comparison
RCUS vs NAVN Comparison
Compare RCUS & NAVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCUS | NAVN |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | RCUS | NAVN |
|---|---|---|
| Price | $26.12 | $15.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $30.27 | $20.92 |
| AVG Volume (30 Days) | 999.3K | ★ 4.2M |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $247,000,000.00 | N/A |
| Revenue This Year | N/A | $26.56 |
| Revenue Next Year | $45.62 | $22.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.06 | $8.11 |
| 52 Week High | $26.40 | $20.27 |
Technical Indicators
Market Signals| Indicator | RCUS | NAVN |
|---|---|---|
| Relative Strength Index (RSI) | 65.38 | 71.31 |
| Support Level | $19.62 | $13.61 |
| Resistance Level | N/A | $18.15 |
| Average True Range (ATR) | 1.56 | 1.03 |
| MACD | 0.30 | 0.25 |
| Stochastic Oscillator | 69.54 | 80.53 |
Price Performance
Historical ComparisonAbout RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About NAVN Navan Inc.
Navan Inc is an end-to-end, AI-powered software platform built to simplify the world-wide business T&E experience, benefiting users, customers, and suppliers. Its leveraged technology to reimagine business travel. The company deliver delightful, personalized experiences for users, efficiency and control for customers, and direct market access for suppliers-all powered by its proprietary AI framework, Navan Cognition. Geographically, the company operates in United States, United Kingdom and Other countries, of which United States derives maximum revenue.